Comparative Pharmacology
Head-to-head clinical analysis: FYCOMPA versus MYSOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYCOMPA versus MYSOLINE.
FYCOMPA vs MYSOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant